Current Research Studies

Cancer – AALL1231: Phase 3 Randomized Trail Investigating Bortexomib on a Modified Augmented BFM Backbone in Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lympphoma

Condition or Therapy:

T-cell acute lymphoblastic leukemia

Category:

Cancer and Blood Disorders
Study Number: AALL1231

What is the goal of this study?

This study compares how patients with newly diagnosed T-cell acute lypmhoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma react when given or not given bortezomib while treated with chemotherapy.

Who can join the study?

This study may be a good fit for children and young adults who:

  • are 2 to 30 years old, and
  • are newly diagnosed with T-lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma (T-LLy) stages II-IV.

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.


Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins